Skip to main content
. 2014 Dec 15;74(6):1156–1163. doi: 10.1136/annrheumdis-2014-206359

Figure 1.

Figure 1

(A) Study design (double-blind period) and (B) patient disposition. ACR, American College of Rheumatology; AE, adverse event; CZP, certolizumab pegol; DMARDs, disease-modifying antirheumatic drug; MARVELOUS, MAgnetic Resonance image VErified earLy respOnse on rheUmatoid factor positive arthritiS; RA, rheumatoid arthritis.